N-of-One, Inc.

N-of-One, Inc. is a molecular decision support company in the Biotechnology and Health Care industries, founded in 2008 and headquartered in the United States. The company's slogan, "Relevant, timely precision oncology treatment options drive real world impact," highlights its commitment to providing clinicians with concise, accurate, and clinically meaningful interpretations of molecular test results. N-of-One is now part of the QIAGEN family, signaling its integration into a larger network of life science and molecular diagnostics solutions. N-of-One's focus on empowering clinicians by providing the highest quality clinical interpretation of molecular test results sets it apart in the industry. Their approach dramatically shortens the time from test results to therapeutic strategy options for each case, enabling faster and more informed decision-making in patient care. It's essential to note that N-of-One does not operate as a diagnostic laboratory or a bioinformatics company; instead, it exists solely to support clinicians in making the best therapeutic decisions. In July 2016, the company received a notable $7.00M Series B investment from Excel Venture Management and Providence Ventures. This funding signifies the confidence and support of established investors in N-of-One's mission and potential for growth within the precision oncology and molecular decision support markets. As part of the QIAGEN family, N-of-One is positioned to leverage its expertise and expand its impact, ultimately contributing to advancements in personalized medicine and oncology treatment.